

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Lurasidone hydrochloride

March 17, 2026

Therapeutic category

Psychotropic agents

Non-proprietary name

Lurasidone hydrochloride

Safety measure

PRECAUTIONS should be revised.

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.
 This English version is intended to be a reference material to provide convenience for users.
 In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revised language is underlined.

Current			Revision		
<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving drugs that strongly inhibit CYP3A4 (itraconazole, voriconazole, miconazole (oral dosage form, oral preparation, injectable dosage forms), fluconazole, fosfluconazole, posaconazole, preparations containing ritonavir, darunavir, atazanavir, fosamprenavir, ensitrelvir, preparations containing cobicistat, clarithromycin, lonafarnib)</p>			<p>2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.)</p> <p>Patients receiving drugs that strongly inhibit CYP3A4 (itraconazole, voriconazole, miconazole (oral dosage form, oral preparation, injectable dosage forms), fluconazole, fosfluconazole, posaconazole, preparations containing ritonavir, darunavir, atazanavir, fosamprenavir, ensitrelvir, preparations containing cobicistat, clarithromycin, lonafarnib, <u>ceritinib</u>)</p>		
<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>			<p>10. INTERACTIONS</p> <p>10.1 Contraindications for Co-administration (Do not co-administer with the following.)</p>		
Drugs	Signs, symptoms, and treatment	Mechanism/risk factors	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
<p>Drugs that strongly inhibit CYP3A4</p> <p>Itraconazole Voriconazole Miconazole (oral dosage form, oral preparation, injectable dosage forms) Fluconazole Fosfluconazole Posaconazole Preparations containing ritonavir Darunavir</p>	<p>The blood concentration of this drug may increase, and the effects may be enhanced.</p>	<p>The metabolism of this drug is suppressed, leading to an increase in the blood concentration of this drug.</p>	<p>Drugs that strongly inhibit CYP3A4</p> <p>Itraconazole Voriconazole Miconazole (oral dosage form, oral preparation, injectable dosage forms) Fluconazole Fosfluconazole Posaconazole Preparations containing ritonavir Darunavir</p>	<p>The blood concentration of this drug may increase, and the effects may be enhanced.</p>	<p>The metabolism of this drug is suppressed, leading to an increase in the blood concentration of this drug.</p>

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Atazanavir Fosamprenavir Ensitrelvir Preparations containing cobicistat Clarithromycin Lonafarnib			Atazanavir Fosamprenavir Ensitrelvir Preparations containing cobicistat Clarithromycin Lonafarnib <u>Ceritinib</u>		